---Advertisement---3
Alnylam Pharmaceuticals (NASDAQ: ALNY) has received a reaffirmed Buy rating from H.C. Wainwright, with a price target of $570.00, driven by compelling Phase 3 ...

Real News Hub is a U.S. breaking news with focus on Import Medical Device License, MD 14, Guest Post, finance, insurance, economy, and tech. Real News Hub delivers real facts for American readers.
2015 - 2026 © www.realnewshub.com • All rights reserved
WhatsApp us
WhatsApp Group